Penumbra Inc.
Penumbra, Inc. Announces Agreement to be Acquired by Boston Scientific Corporation
Summary
Penumbra, Inc. has entered into an Agreement and Plan of Merger with Boston Scientific Corporation. Under the terms of the agreement, Penumbra shareholders will receive either 3.8721 Boston Scientific shares for each Penumbra share or $374.00 in cash, with the majority of shares receiving the cash option. The merger is subject to conditions including stockholder approval and regulatory clearances. Additionally, Penumbra announced preliminary financial results for Q4 and full year 2025, showing revenue growth of approximately 21.4% to 22.0% for Q4 and 17.3% to 17.5% for the full year, with gross margins of 67.9% to 68.1% for Q4 and 67.1% for the full year.
Profitelligence Alerts
Get alerts for PEN
Be first to know when Penumbra Inc. files with the SEC.
Filing Categories
Advertisement
About Penumbra Inc.
Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices. Known for its customer-centric approach, the company operates within the specialized field of interventional therapies, particularly in neuro and vascular medical devices. Penumbra’s products are crucial for addressing critical conditions such as stroke and peripheral artery diseases. By pioneering minimally invasive solutions, the company significantly contributes to enhancing patient outcomes and reshaping intervention methods in the medical field. Founded in 2004 and headquartered in Alameda, California, Penumbra plays a vital role in the medical device industry with its commitment to advancing healthcare technologies. Its solutions are not only pivotal in specialized medical procedures but also support the healthcare ecosystem's broader objective of improving care and saving lives, making it a key entity amongst healthcare providers and hospitals worldwide.
Official SEC Documents
Advertisement